|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2008-3-19
|
|
pubmed:abstractText |
Regulation of epidermal growth factor receptor (EGFR) signaling pathways may play a relevant role in determining the activity of cetuximab therapy in patients with metastatic colorectal cancer (MCRC). We investigated possible associations between genetic variants and clinical outcomes of MCRC patients treated with cetuximab-irinotecan salvage therapy.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Genetic Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin,
http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/cetuximab,
http://linkedlifedata.com/resource/pubmed/chemical/irinotecan
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:AndreoniFrancescaF,
pubmed-author:BisonniRenatoR,
pubmed-author:CanestrariEmanueleE,
pubmed-author:CatalanoVincenzoV,
pubmed-author:FalconeAlfredoA,
pubmed-author:FlorianiIreneI,
pubmed-author:FontanaAndreaA,
pubmed-author:GiustiniLucioL,
pubmed-author:GrazianoFrancescoF,
pubmed-author:HumarBostjanB,
pubmed-author:LoupakisFotiosF,
pubmed-author:MagnaniMauroM,
pubmed-author:MaltesePaoloP,
pubmed-author:MasiGianlucaG,
pubmed-author:RulliElianaE,
pubmed-author:RuzzoAnnamariaA,
pubmed-author:SantiniDanieleD,
pubmed-author:SchiavonGaiaG,
pubmed-author:ToniniGiuseppeG,
pubmed-author:TorresiUmbertoU
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1427-34
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:18349392-Adult,
pubmed-meshheading:18349392-Aged,
pubmed-meshheading:18349392-Analysis of Variance,
pubmed-meshheading:18349392-Antibodies, Monoclonal,
pubmed-meshheading:18349392-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18349392-Camptothecin,
pubmed-meshheading:18349392-Colorectal Neoplasms,
pubmed-meshheading:18349392-Disease Progression,
pubmed-meshheading:18349392-Disease-Free Survival,
pubmed-meshheading:18349392-Drug Administration Schedule,
pubmed-meshheading:18349392-Female,
pubmed-meshheading:18349392-Fluorouracil,
pubmed-meshheading:18349392-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:18349392-Genetic Markers,
pubmed-meshheading:18349392-Haplotypes,
pubmed-meshheading:18349392-Humans,
pubmed-meshheading:18349392-Infusions, Intravenous,
pubmed-meshheading:18349392-Injections, Intravenous,
pubmed-meshheading:18349392-Leucovorin,
pubmed-meshheading:18349392-Male,
pubmed-meshheading:18349392-Middle Aged,
pubmed-meshheading:18349392-Organoplatinum Compounds,
pubmed-meshheading:18349392-Polymorphism, Genetic,
pubmed-meshheading:18349392-Proportional Hazards Models,
pubmed-meshheading:18349392-Prospective Studies,
pubmed-meshheading:18349392-Receptor, Epidermal Growth Factor,
pubmed-meshheading:18349392-Salvage Therapy,
pubmed-meshheading:18349392-Signal Transduction,
pubmed-meshheading:18349392-Tumor Markers, Biological
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
|
|
pubmed:affiliation |
Medical Oncology Unit, Hospital of Pesaro, Pesaro, Italy. frada@tin.it
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
